779 related articles for article (PubMed ID: 16342002)
1. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.
Gouzoulis-Mayfrank E; Heekeren K; Neukirch A; Stoll M; Stock C; Obradovic M; Kovar KA
Pharmacopsychiatry; 2005 Nov; 38(6):301-11. PubMed ID: 16342002
[TBL] [Abstract][Full Text] [Related]
2. Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis.
Heekeren K; Neukirch A; Daumann J; Stoll M; Obradovic M; Kovar KA; Geyer MA; Gouzoulis-Mayfrank E
J Psychopharmacol; 2007 May; 21(3):312-20. PubMed ID: 17591658
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of return in the human 5HT2A agonist and NMDA antagonist model of psychosis.
Gouzoulis-Mayfrank E; Heekeren K; Neukirch A; Stoll M; Stock C; Daumann J; Obradovic M; Kovar KA
Neuropsychopharmacology; 2006 Feb; 31(2):431-41. PubMed ID: 16123739
[TBL] [Abstract][Full Text] [Related]
4. Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis.
Daumann J; Wagner D; Heekeren K; Neukirch A; Thiel CM; Gouzoulis-Mayfrank E
J Psychopharmacol; 2010 Oct; 24(10):1515-24. PubMed ID: 19304859
[TBL] [Abstract][Full Text] [Related]
5. Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis.
Heekeren K; Daumann J; Neukirch A; Stock C; Kawohl W; Norra C; Waberski TD; Gouzoulis-Mayfrank E
Psychopharmacology (Berl); 2008 Jul; 199(1):77-88. PubMed ID: 18488201
[TBL] [Abstract][Full Text] [Related]
6. Does ketamine mimic aspects of schizophrenic speech?
Covington MA; Riedel WJ; Brown C; He C; Morris E; Weinstein S; Semple J; Brown J
J Psychopharmacol; 2007 May; 21(3):338-46. PubMed ID: 17591660
[TBL] [Abstract][Full Text] [Related]
7. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
[TBL] [Abstract][Full Text] [Related]
8. Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans.
Strassman RJ; Qualls CR; Berg LM
Biol Psychiatry; 1996 May; 39(9):784-95. PubMed ID: 8731519
[TBL] [Abstract][Full Text] [Related]
9. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function.
Krystal JH; Perry EB; Gueorguieva R; Belger A; Madonick SH; Abi-Dargham A; Cooper TB; Macdougall L; Abi-Saab W; D'Souza DC
Arch Gen Psychiatry; 2005 Sep; 62(9):985-94. PubMed ID: 16143730
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis.
Daumann J; Heekeren K; Neukirch A; Thiel CM; Möller-Hartmann W; Gouzoulis-Mayfrank E
Psychopharmacology (Berl); 2008 Nov; 200(4):573-83. PubMed ID: 18649072
[TBL] [Abstract][Full Text] [Related]
11. Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults.
Lofwall MR; Griffiths RR; Mintzer MZ
Exp Clin Psychopharmacol; 2006 Nov; 14(4):439-49. PubMed ID: 17115871
[TBL] [Abstract][Full Text] [Related]
12. The NMDA antagonist model for schizophrenia: promise and pitfalls.
Abi-Saab WM; D'Souza DC; Moghaddam B; Krystal JH
Pharmacopsychiatry; 1998 Jul; 31 Suppl 2():104-9. PubMed ID: 9754841
[TBL] [Abstract][Full Text] [Related]
13. Ketamine effects on CNS responses assessed with MEG/EEG in a passive auditory sensory-gating paradigm: an attempt for modelling some symptoms of psychosis in man.
Boeijinga PH; Soufflet L; Santoro F; Luthringer R
J Psychopharmacol; 2007 May; 21(3):321-37. PubMed ID: 17591659
[TBL] [Abstract][Full Text] [Related]
14. Acute and chronic effects of ketamine on semantic priming: modeling schizophrenia?
Stefanovic A; Brandner B; Klaassen E; Cregg R; Nagaratnam M; Bromley LM; Das RK; Rossell SL; Morgan CJ; Curran HV
J Clin Psychopharmacol; 2009 Apr; 29(2):124-33. PubMed ID: 19512973
[TBL] [Abstract][Full Text] [Related]
15. Effects of the NMDA receptor antagonist ketamine in electrically induced A delta-fiber pain.
Rabben T
Methods Find Exp Clin Pharmacol; 2000 Apr; 22(3):185-9. PubMed ID: 10893703
[TBL] [Abstract][Full Text] [Related]
16. Prolonged analgesic effect of ketamine, an N-methyl-D-aspartate receptor inhibitor, in patients with chronic pain.
Rabben T; Skjelbred P; Oye I
J Pharmacol Exp Ther; 1999 May; 289(2):1060-6. PubMed ID: 10215688
[TBL] [Abstract][Full Text] [Related]
17. Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia.
D'Souza DC; Ahn K; Bhakta S; Elander J; Singh N; Nadim H; Jatlow P; Suckow RF; Pittman B; Ranganathan M
Biol Psychiatry; 2012 Nov; 72(9):785-94. PubMed ID: 22717030
[TBL] [Abstract][Full Text] [Related]
18. Effects of ketamine in normal and schizophrenic volunteers.
Lahti AC; Weiler MA; Tamara Michaelidis BA; Parwani A; Tamminga CA
Neuropsychopharmacology; 2001 Oct; 25(4):455-67. PubMed ID: 11557159
[TBL] [Abstract][Full Text] [Related]
19. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.
Malhotra AK; Pinals DA; Weingartner H; Sirocco K; Missar CD; Pickar D; Breier A
Neuropsychopharmacology; 1996 May; 14(5):301-7. PubMed ID: 8703299
[TBL] [Abstract][Full Text] [Related]
20. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
Large CH
J Psychopharmacol; 2007 May; 21(3):283-301. PubMed ID: 17591656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
